

ArGEN-X BV: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

ArGEN-X BV Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, September 23, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by [arGEN-X BV](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Complete Report @

<https://www.wiseguyreports.com/reports/649761-argen-x-bv-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of arGEN-X BV
- The report provides overview of arGEN-X BV including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses arGEN-X BV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features arGEN-X BV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects



Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649761-argen-x-bv-product-pipeline-review-2016>

Reasons to buy

- Evaluate arGEN-X BV's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for arGEN-X BV
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding arGEN-X BV's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have any query @ <https://www.wiseguyreports.com/enquiry/649761-argen-x-bv-product-pipeline-review-2016>

Table of Content

| | |
|--|----|
| Key Facts | 5 |
| arGEN-X BV - Research and Development Overview | 6 |
| Key Therapeutic Areas | 6 |
| arGEN-X BV - Pipeline Review | 9 |
| Pipeline Products by Stage of Development | 9 |
| Pipeline Products - Monotherapy | 10 |
| Pipeline Products - Partnered Products | 11 |
| Partnered Products/Combination Treatment Modalities | 12 |
| Pipeline Products - Out-Licensed Products | 13 |
| Out-Licensed Products/Combination Treatment Modalities | 14 |
| arGEN-X BV - Pipeline Products Glance | 15 |
| arGEN-X BV - Clinical Stage Pipeline Products | 15 |
| Phase I Products/Combination Treatment Modalities | 15 |
| arGEN-X BV - Early Stage Pipeline Products | 16 |
| Preclinical Products/Combination Treatment Modalities | 16 |
| Discovery Products/Combination Treatment Modalities | 17 |
| arGEN-X BV - Drug Profiles | 18 |
| ARGX-110 | 18 |
| Product Description | 18 |
| Mechanism of Action | 18 |
| R&D Progress | 18 |
| ARGX-111 | 22 |
| Product Description | 22 |
| Mechanism of Action | 22 |
| R&D Progress | 22 |
| ARGX-113 | 24 |
| Product Description | 24 |
| Mechanism of Action | 24 |
| R&D Progress | 24 |
| ARGX-112 | 26 |
| Product Description | 26 |

Mechanism of Action 26
R&D Progress 26
ARGX-115 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibodies for Cancer, Immunology and Metabolic Disorders 28
Product Description 28
Mechanism of Action 28
R&D Progress 28

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649761 □

Continued...

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.